Related Experiment Video

Updated: Aug 7, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Increase in peripheral benzodiazepine receptors on monocytes in fibromyalgia

P Faggioli1, L Giani, R Chianese

  • 1Internal Medicine and Rheumatology Unit, Legnano Hospital, Via Candiani 2, 20025 Legnano, Milan, Italy. medicina2legnano@ao-legnano.it

Rheumatology (Oxford, England)
|July 15, 2004
PubMed
Abstract

Insights

Peripheral Benzodiazepine Receptors (PBRs) are upregulated on leukocytes in fibromyalgia patients, particularly monocytes. This finding may explain pain regulation and therapeutic responses to benzodiazepines in fibromyalgia.

Area of Science:

  • Immunology
  • Neuroscience
  • Pain Medicine

Background:

  • Fibromyalgia is a chronic pain condition with complex pathophysiology.
  • Peripheral Benzodiazepine Receptors (PBRs) are implicated in various physiological processes, including inflammation and pain signaling.

Purpose of the Study:

  • To investigate the expression levels of PBRs on leukocytes in patients with primary fibromyalgia.
  • To explore the potential role of PBRs in pain perception and immune modulation in fibromyalgia.

Main Methods:

  • Flow cytometry and indirect immunofluorescence were used to quantify PBR expression.
  • Leukocyte subsets including monocytes, lymphocytes, and granulocytes were analyzed in 20 fibromyalgia patients and controls.

Main Results:

  • A statistically significant upregulation of PBR expression was observed on monocytes in fibromyalgia patients compared to controls (26.74 +/- 14.84 MIF vs. 17.45 +/- 8.54 MIF, P < 0.023).
  • Increased PBR expression, though not statistically significant, was also noted on lymphocytes and granulocytes in fibromyalgia patients.

Conclusions:

  • The overincrease of monocyte PBRs in fibromyalgia suggests a potential link to pain regulation abnormalities or inflammatory processes.
  • These findings may elucidate the mechanisms underlying the therapeutic efficacy of benzodiazepines in managing fibromyalgia symptoms.

More Related Videos

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Concept Videos

Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...